Novavax COVID-19 vaccine authorized for U.S. teens

Dow Jones2022-08-20

MW Novavax COVID-19 vaccine authorized for U.S. teens

The Food and Drug Administration authorized Novavax Inc.'s COVID-19 vaccine for use in U.S. teenagers on Friday. Novavax's recombinant protein-based vaccine uses different technology than the mRNA shots developed by Moderna Inc. and BioNTech SE , and received an emergency-use authorization by the FDA for adults in July. The vaccine still requires a policy recommendation for use by the Centers for Disease Control, which followed the FDA by about a week when authorizing the Novavax shot for adults. Novavax shares ticked 0.6% higher in late trading Friday, after the announcement; the stock has declined nearly 75% so far this year, as the S&P 500 index has dropped 11.8%.

-Jeremy C. Owens

$(END)$ Dow Jones Newswires

August 19, 2022 19:14 ET (23:14 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • EKE
    2022-08-20
    EKE
    [Call] [Call] [Call] [Call] [Call] [Call] [Call] [Call] 
Leave a comment